Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging

Breast Cancer Research and Treatment
Yong YueBenedick Fraass

Abstract

This study aims to stratify prognosis of triple-negative breast cancer (TNBC) patients using pre-treatment 18F-FDG-PET/CT, alone and with correlation to immunohistochemistry biomarkers. 200 consecutive TNBC breast cancer patients treated between 2008 and 2012 were retrieved. Among the full cohort, 79 patients had pre-treatment 18F-FDG-PET/CT scans. Immunostaining status of basal biomarkers (EGFR, CK5/6) and other clinicopathological variables were obtained. Three PET image features were evaluated: maximum uptake values (SUVmax), mean uptake (SUVmean), and metabolic volume (SUVvol) defined by SUV > 2.5. All variables were analyzed versus disease-free survival (DFS) using univariate and multivariate Cox analysis, Kaplan-Meier curves, and log-rank tests. The optimal cutoff points of variables were estimated using time-dependent survival receiver operating characteristic (ROC) analysis. All PET features significantly correlated with proliferation marker Ki-67 (all p < 0.010). SUVmax stratified the prognosis of TNBC patients with optimal cutoff derived by ROC analysis (≤3.5 vs. >3.5, AUC = 0.654, p = 0.006). SUVmax and EGFR were significant prognostic factors in univariate and multivariate Cox analyses. To integrate prognosis of bio...Continue Reading

References

Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N AvrilM Schwaiger
Aug 30, 2000·Nature·C M PerouD Botstein
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N AvrilM Schwaiger
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clifford A HudisJo Anne Zujewski
Mar 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maggie C U CheangTorsten O Nielsen
Apr 26, 2008·International Journal of Radiation Oncology, Biology, Physics·David GroheuxJean-Louis Misset
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel S ParkerPhilip S Bernard
Mar 20, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Joseph R OsborneSteven Larson
May 25, 2010·The American Journal of Surgical Pathology·Aye Aye ThikePuay Hoon Tan
Mar 23, 2011·Journal of the National Cancer Institute·Alan MackayJorge S Reis-Filho
Sep 1, 2011·Nature Reviews. Clinical Oncology·Britta WeigeltJorge S Reis-Filho
Jun 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa A CareyEric P Winer
Aug 9, 2012·Cancer Informatics·Xi ChenJennifer A Pietenpol
Dec 6, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·David GroheuxMarc Espié
Oct 12, 2013·The Journal of Pathology·Brian D Lehmann, Jennifer A Pietenpol
Nov 8, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Alexandre CochetFrançois Brunotte
Dec 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicholas C Turner, Jorge S Reis-Filho
Nov 30, 2014·European Journal of Nuclear Medicine and Molecular Imaging·D GroheuxE Hindié
Dec 3, 2014·The Lancet Oncology·David Groheux
Feb 24, 2015·Breast Cancer Research and Treatment·Kenjiro AogiMorihito Okada

❮ Previous
Next ❯

Citations

Aug 30, 2016·The Breast : Official Journal of the European Society of Mastology·Tomoko HiguchiYasuo Miyoshi
Oct 18, 2016·Frontiers in Oncology·Egidio IorioFranca Podo
Apr 9, 2017·BMC Medical Research Methodology·Adina Najwa KamarudinRuwanthi Kolamunnage-Dona
Jun 6, 2018·Annals of Nuclear Medicine·David Molina-GarcíaVíctor M Pérez-García
Feb 17, 2017·British Journal of Cancer·Onofrio Antonio CatalanoBruce Robert Rosen
May 11, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Joohee LeeKyung-Han Lee

❮ Previous
Next ❯

Methods Mentioned

BETA
dissection

Software Mentioned

SPSS
R
VelocityAI

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Zhengjun YangXuchen Cao
Breast Cancer Research and Treatment
Maria Aparecida NagaiFernando A Soares
European Journal of Nuclear Medicine and Molecular Imaging
Janet F EaryErnest U Conrad
© 2021 Meta ULC. All rights reserved